🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 92840H400 (prev. 92840H202 )
- Market Cap
- Micro Cap
- Previous Symbol
- VSTA (changed 5/6/2016)
Business: VistaGen Therapeutics, Inc.is a late clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with depression, other diseases and disorders related to the central nervous system and cancer. It uses stem cell technology platform for drug rescue, to identify and develop new chemical entities for its internal drug candidate pipeline.
Notes: June 06, 2023 -- Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common stock, at a ratio of one-for-thirty unanimously approved by its Board of Directors. Vistagen common stock will begin trading on a split-adjusted basis at the opening of trading on the Nasdaq Capital Market on Wednesday, June 7, 2023. The Company’s shares will continue to trade on the Nasdaq Capital Market under the symbol “VTGN,” with a new CUSIP number, 92840H400.
Company Contact
- CEO
- Shawn K. Singh
- CFO
- Nick Tressler
- Headquarters
- 343 Allerton Avenue, South San Francisco, CA 94080
- Phone
- 650-577-3600
- Fax
- 800-482-2602
- Investor Relations
- Mark A. McPartland · 650-577-3606 · markmcp@vistagen.com